Diaceutics’ suite of companion diagnostic commercialization services puts patients first at ASCO 2019 - Diaceutics

Diaceutics’ suite of companion diagnostic commercialization services puts patients first at ASCO 2019

May 7th, 2019



Patients themselves are the focus of this year’s annual meeting of the American Society of Clinical Oncology (ASCO), which will be held May 31 through June 4, 2019 at McCormick Place in Chicago, Illinois. The meeting’s official theme is “Caring for Every Patient, Learning from Every Patient.” That focus on the patient starts with an early and accurate diagnosis, which is the mission of Diaceutics.

In the words of the CEO of Diaceutics, Peter Keeling, “Diaceutics was founded out of a desire to get more patients access to improved healthcare. We are giving patients a higher likelihood of getting better by supporting access to the right test to determine the right treatment at the right time.”

And that’s why Diaceutics will be onsite at ASCO 2019 inviting all those interested in learning more about options in partnering for companion diagnostic commercialization. A data analytics and implementation services provider focused strictly on precision medicine, Diaceutics has established a suite of data-driven products powered by the real-world diagnostic testing data held in its proprietary database. These solutions are focused on optimizing our pharmaceutical clients’ strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines—ultimately putting patients first in the diagnostic patient journey.

Diaceutics’ services fall into the following 4 sequential modules:

  • Landscape – Comprehensive reviews of the testing environment for pharmaceutical companies, identifying risks and opportunities while providing essential insight into the strategic decisions that need to be made in advance of a launch.
  • Planning – Advising on steps to ensure rapid and effective test adoption, including advice on how tests should be developed, who these tests should be developed with, and how they may be optimally communicated to physicians and patients.
  • Implementation – Identifying and solving issues with leading laboratories relating to the adoption and efficacy of testing.
  • Tracking – Ongoing post launch analysis to understand how tests are being adopted and utilized to determine if they are promoting or restricting access to precision therapy.

Learn more about Diaceutics by clicking here.

Diaceutics recently became the fourth Northern Irish company to list on the London Stock Exchange with its initial public offering (IPO) on March 21, 2019. Diaceutics is currently trading under the AIM ticker symbol DXRX. The IPO is a testament to Diaceutics’ commitment to patients everywhere, following 13 years spent on the ground mining the diagnostic testing market, collating large amounts of laboratory, patient (anonymized and aggregated), claims and payor data in order to deliver companion diagnostic strategies to clients.

Find out how partnering with Diaceutics may help you help patients live longer and enjoy a better quality of life through earlier, accurate diagnostic testing.

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications